Innate Pharma (IPHA)
(Delayed Data from NSDQ)
$2.15 USD
+0.01 (0.23%)
Updated Aug 6, 2025 01:49 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Innate Pharma S.A. Sponsored ADR has a market cap of $197.73M, which represents its share price of $2.15 multiplied by its outstanding shares number of 92.18M. As a small-cap company, IPHA's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
IPHA 2.15 +0.01(0.23%)
Will IPHA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IPHA based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for IPHA
Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025 | IPHA Stock News
Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference | IPHA ...
12 Health Care Stocks Moving In Monday's Pre-Market Session
Innate Pharma (IPHA) Receives Buy Rating with Encouraging Outlook
Innate Pharma initiated with bullish view at BTIG, here's why